stockrow
Saturday 7 November 2026
Export NKGN’s income statement to Excel — free account
NKGen Biotech, Inc.
NKGN Healthcare Biotechnology
NKGen Biotech, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $77,000.00.
- EPS
- +232.0%
- Free cash flow
- +28.7%
Quarter to March 2025, against a year earlier
0.01
0.00
0.00%
Follow NKGN
Alert me
| Older periods | Jun '24 | Sep '24 | Dec '24 | Mar '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.01 | 0.01 | 0.00 | 0.00 | |
Current Ratio |
0.02 | 0.02 | 0.04 | 0.05 | |
Net Debt/EBITDA |
(2.43) | (3.11) | (9.07) | (6.89) | |
Debt/Assets |
112.83% | 135.47% | 267.97% | 186.69% | |
Debt/Equity |
(0.25) | (0.43) | (0.62) | (0.59) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.37 | (0.62) | 0.24 | (0.18) | |
Capex/Depreciation |
(0.05) | (0.05) | (0.05) | (0.14) | |
Interest Coverage |
(11.53) | (14.38) | (9.51) | (9.17) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.25) | (0.13) | (0.24) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.13) | (0.24) | (0.06) | |
Cash per Share |
0.01 | 0.01 | 0.01 | 0.00 | |
Shareholders Equity per Share |
(2.88) | (1.61) | (2.42) | (1.10) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.88) | (1.61) | (2.42) | (1.10) | |
Free Cash Flow |
(6.01) | (3.91) | (6.97) | (2.85) | |
Working Capital |
(50.16) | (36.21) | (55.51) | (41.51) | |
Capital Expenditures |
(0.01) | (0.02) | (0.02) | (0.05) | |
Net Current Asset Value |
(84.12) | (61.13) | (83.68) | (63.79) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.63 | 14.79 | 14.53 | 16.03 | |
Average Assets |
39.63 | 20.10 | 16.36 | 16.08 | |
Average Common Equity |
(39.13) | (43.84) | (64.30) | (52.69) |
Columns are period end dates · fundamentals updated 26 Oct 2026